维普中文期刊产品整合服务
89篇 您的检索式:作者名="Folprecht G"
    题名 作者 年代 出处 被引量
1Cetuximab plus FOLFIRI:final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome 显示文摘Van CE Lang I Folprecht G 2010J Clin Onco12010,28,15:1
2Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates显示文摘Folprecht G Grothey A Alberts S 2005Ann 0ncol2005,16,8:1
3Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial 显示文摘Folprecht G Gruenberger T Bechstein WO 2010Lancet Oncol2010,11,1:1
4Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials 显示文摘Folprecht G Cunningham D Ross P 2004Ann Oncol2004,15,9:1
5Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial显示文摘Folprecht G Gruenberger T Bechstein WO 2010Lancet Oncol2010,11,1:1
6Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates 显示文摘Folprecht G Grothey A Alberts S 2005Ann Oncol2005,16,8:1
7Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab:the CELIM randomised phase 2 trial显示文摘Folprecht G Gruenberger T Bechstein WO 2010Lancet Oncol2010,11,:1
8Accomplishments in 2008 in the management of curable metastatic colorectal cancer显示文摘Adam R Hoti E Folprecht G 2009Gas- trointest Canrer Res2009,3,2:1
9Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma显示文摘 Lutz M P Schoffski P 2006Ann Oncol2006,17,3:1
10Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab , the CELIM randomised phase 2 trial 显示文摘Folprecht G Gruenberger T Bechstein WO 2010Lancet Onco12010,11,1:1
11Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer显示文摘Folprecht G Kohne CH Lutz MP 2007Cancer Treat Res2007,134,:1
12Cetuximab and irinote-can/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma显示文摘Folprecht G Lutz MP Sch(o)ffski P 2006Ann Oncol2006,17,3:1
13The role of new agents in the treatment of coloreetal cancer显示文摘Folprecht G K(o)hne C H 2004Oncology2004,66,1:1
14Introduction: Advances in treatment of metastatic colorectal cancer显示文摘Folprecht G 2008Cancer Treat Rev2008,34,12:1
15Neoadjuvant treatment of unresectable colorectal liver metastases:correlation between tumour response and resection rates显示文摘Folprecht G Grothey A Alberts S 2005Ann Oncol2005,16,8:1
16Cetuximab and ironotecan /5-fluorouracil/folinic acid is a safe combination for the first(-)line treatment of patients with epidermal growth foctor receptor expressing metastatic colorectal carcinoma显示文摘Folprecht G Lutz M P Schoffski P 2005Ann Oncol2005,22,:1
17Chemotherapy in elderly patients with colorectal cancer 显示文摘KOHNE C H FOLPRECHT G GOLDBERG R M 2008Oncologist2008,13,4:1
18The role of new agents in the treatment of colorectal cancer显示文摘Folprecht G Khne CH 0,,01:1
19Cetuximab andirinotecan/5-fluorouracil/folinic acid is a safe combination for the firstline treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma 显示文摘Folprecht G Lutz MP Schoffski P 2006Ann Oncol2006,17,3:1
20Tumour response and secondary resectability of colorectal liver metastases following neo-adjuvant chemotherapy with ce- tuximab:the CELIM randomised phase 2 trial 显示文摘Folprecht G Gruenberger T Bechstein WO 2010Lancet Oncol2010,11,1:1
返回顶部 每页显示:
共5页 首页 上一页 第1页 下一页 末页 /5 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费